WCMNY
MRSN

Westchester Capital Management (New York)’s Mersana Therapeutics MRSN Stock Holding History

Westchester Capital Management (New York)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20
Closed -$7K – 84
2017
Q2 		$7K Buy
+20
New +$6.92K ﹤0.01% 83

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westchester Capital Management (New York)'s MRSN Position: Q3 2017 in Review

Westchester Capital Management (New York) sold out of Mersana Therapeutics (MRSN) in Q3 2017, closing a stake of 20 shares — an estimated $7K sold.

Westchester Capital Management (New York) first reported a position in MRSN in Q2 2017 and held it in 1 quarter. The position peaked at $7K in Q2 2017. 42 funds tracked by Wall St. Rank hold MRSN as of Q3 2017.

  • Westchester Capital Management (New York) reported no remaining Mersana Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 20 Mersana Therapeutics shares in Q3 2017, an estimated $7K.
  • Westchester Capital Management (New York) first reported a position in Mersana Therapeutics in Q2 2017 and held it in 1 quarter.
  • Westchester Capital Management (New York)'s Mersana Therapeutics position peaked at $7K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2017.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2017, filed 14 Nov 2017.